



#6

1645

PATENT  
Customer No. 22,852  
Attorney Docket No. 3495.0166-02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )

Ara HOVANESSIAN et al. )

Application No.: 09/825,886 )

Filed: April 5, 2001 )

For: A NOVEL CELL SURFACE )  
RECEPTOR FOR HIV )  
RETROVIRUSES, THERAPEUTIC )  
AND DIAGNOSTIC USES )

RECEIVED

Group Art Unit: 1645 OCT 22 2001

Examiner: Zeman, R. TECH CENTER 1600/2900

Commissioner for Patents and Trademarks  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for this application.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

English abstracts of the non-English documents are enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: October 18, 2001

By: Rebecca M. McNeill  
Rebecca M. McNeill  
Reg. No. 43,796

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

RECEIVED

OCT 22 2001

-inter 1600/2900

Atty. Docket No.	03495.0166-02000	Serial No.	09/825,886			
Applicant	Hovanessian et al.					
Filing Date	April 5, 2001		Group:	1645		
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,652,333	July 29, 1997	Fung et al.	530	326	09/06/96
<b>FOREIGN PATENT DOCUMENTS</b>						
	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
	07242566	09/19/95	Japan			Abstract
	WO 94/28915	12/22/94	PCT			Derwent Abstract
	WO 95/29190	11/02/95	PCT			Derwent Abstract
	WO 96/30400	10/03/96	PCT			See 5,652,333
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	<i>Bourbon et al.</i> , "AC Q60500", EMBL Database, November 1, 1996.					
	<i>Bourbon et al.</i> , Sequence and structure of the nucleolin promoter in rodents: characterization of a strikingly conserved CpG island, Gene 68:73-84 (1988).					
	<i>Callebaut et al.</i> , Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death, Virology 218:181-192 (1996).					
	<i>Callebaut et al.</i> , Pseudopeptide TASP inhibitors of HIV entry bind specifically to a 95-kDa cell surface protein, Journal of Biological Chemistry 272(11):7159-7166 (1997).					
	<i>De Verdugo et al.</i> , Characterization of a 100-Kilodalton Binding Protein for the Six Serotypes of Cocksackie B Viruses, Journal of Virology 69(11):6751-6757 (1995).					
	<i>Jordan</i> , At the heart of the nucleolus, Nature 329: 489-490 (1987).					
	<i>Srivastava et al</i> , Cloning and sequencing of the human nucleolin cDNA, FEBS 250: 99-105 (1989).					
	<i>Srivastava et al.</i> , Genomic organization and chromosomal localization of the human nucleolin gene, J. Biol. Chem. 265(25): 14922-14931 (1990).					
	<i>Vaesen et al.</i> , Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII, Biological Chemistry Hoppe-Seyler 375:113-126 (1994).					
	<i>Valenzuela et al.</i> , Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells, Journal of Virology 71(11):8289-8298 (1997).					
Examiner				Date Considered		
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce				